Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Human IL-15 Protein, Fc Tag (Cat. No. IL5-H5257) stimulates proliferation of CTLL-2 cells. The typically EC50 for this effect is 2.483 ng/mL (QC tested).
Biotinylated Human IL-15 R alpha, Fc,Avitag (Cat. No. ILA-H82F4) immobilized on CM5 Chip can bind Human IL-15 Protein, Fc Tag (Cat. No. IL5-H5257) with an affinity constant of 27.7 pM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
BNZ-1 | BNZ132-1-40; BNZ-1; BNZ132-1; BNZ-01; EQ101; EQ-101 | Phase 2 Clinical | Bioniz Therapeutics Inc | Alopecia; Alopecia Areata; Lymphoma, T-Cell, Cutaneous; Leukemia, Large Granular Lymphocytic | Details |
Ordesekimab | HuMab-IL15; AMG-714; PRV-015 | Phase 2 Clinical | Provention Bio Inc, Genmab A/S, Amgen Inc | Arthritis, Rheumatoid; Celiac Disease; Psoriasis; Lymphoma, T-Cell; Vitiligo | Details |
HCW-9218 | HCW-9218 | Phase 2 Clinical | HCW Biologics Inc | Solid tumours; Pancreatic Neoplasms; Pulmonary Fibrosis | Details |
NY-ESO-1 TCR/IL-15 NK | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center, Syena, Replay Holdings LLC | Sarcoma, Synovial; Multiple Myeloma; Liposarcoma, Myxoid | Details | |
IL15-transpresenting WT1-targeted Dendritic Cell Vaccine(Antwerp University Hospital) | Phase 2 Clinical | Antwerp University Hospital | Liver Neoplasms; Ovarian Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms | Details | |
CAR-5/IL-15-transduced CB-NK cell therapy | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Hematologic Neoplasms | Details | |
Recombinant Human IL12/15-PDL1B Herpes Simplex Type I Oncolytic Virus(CNBG) | VG-161 | Phase 2 Clinical | Cnbg-Virogin Biotech (Shanghai) Ltd | Solid tumours; Liver Neoplasms; Biliary Tract Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Sarcoma; Cholangiocarcinoma; Carcinoma, Hepatocellular | Details |
XmAb24306 | XmAb-24306; RG-6323; RO-7310729; XmAb-306 | Phase 1 Clinical | Genentech Inc, Xencor Inc | Solid tumours; Neoplasms; Multiple Myeloma | Details |
SIM-0237 | SIM-0237 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Solid tumours; Urinary Bladder Neoplasms | Details |
CYTO-102 | CYTO-NK-102; CYTO-102; COH06 | Phase 1 Clinical | CytoImmune Therapeutics Inc | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
VG-201 | VG-201 | Phase 1 Clinical | ViroGin Biotech Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
VG-203 | VG-203; VG2062; VG-2062 | Phase 1 Clinical | ViroGin Biotech Ltd, Shanghai Funuojian Biotechnology Co Ltd, Virogin Biotech (Shenzhen) Ltd, Fenojian Biotechnology (Nantong) Co Ltd | Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Breast Neoplasms | Details |
ACTM-838 | ACTM838 | Phase 1 Clinical | Actym Therapeutics Inc | Solid tumours | Details |
CALY-002 | CALY-002 | Phase 1 Clinical | Idd Biotech | Eosinophilic Esophagitis; Celiac Disease | Details |
This web search service is supported by Google Inc.